comparemela.com

Latest Breaking News On - Refractory acute myeloid - Page 1 : comparemela.com

Why Is GlycoMimetics Stock Falling In Pre-market?

GlycoMimetics, Inc. (GLYC) reported topline results from Phase 3 global pivotal study of uproleselan in 388 patients with Relapsed/Refractory Acute Myeloid Leukemia.

More such health newsGlycomimetics incRefractory acute myeloid

Natural Killer (NK) Cell Therapy Pipeline Research Report

Dublin, April 19, 2024 (GLOBE NEWSWIRE) The

Pharma monalizumabKiadis pharmaPersongen biotherapeuticsRoute of administrationCellprotect nordic pharmaceuticalsAltor bioscience corporationVecura at karolinska university hospitalKarolinska university hospital in huddingeNatural killerEmerging drugsNectar therapeuticsInnate pharma monalizumabInnate pharmaSquamous cell carcinomaFive prime therapeutics bemarituzumabMultiple myeloma

VCAR33ALLO by Vor BioPharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval

VCAR33ALLO is under clinical development by Vor BioPharma and currently in Phase II for Refractory Acute Myeloid Leukemia.

United statesUnited kingdomCompany profileCompany profilesPuretech health plcVor biopharmaRefractory acute myeloidRefractory acute myeloid leukemiaTreatment system

DVX-201 by Coeptis Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval

DVX-201 is under clinical development by Coeptis Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.

United statesGlobaldata pharmaceutical intelligence centerCoeptis therapeuticsRefractory acute myeloidRefractory acute myeloid leukemiaPhase transition success rate modelPharmaceutical intelligence

November 2022 CDMO Opportunities And Threats Report

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities.

United kingdomMibe gmbh arzneimittelImmunbiologischeforschung gmbLaboratorios farmaceuticos roviMinaris regenerative medicineGlypharma therapeutic incNational resilience incAstrazeneca plcMerck co incKaruna therapeutics incBiovac instituteAbbvie incModerna incExcella gmbh coRoche ltdRigel pharmaceuticals inc

vimarsana © 2020. All Rights Reserved.